Professor of Hematology
Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh
HTC, Chairman- Lab One Foundation & Director, WBDR- HTC (BSMMU)
We are currently providing care and support to over 800 registered hemophilia patients through our Hemophilia Treatment Centers (HTCs) at BSMMU and Lab One Foundation. Our services include outpatient, inpatient, and emergency care facilities tailored specifically for individuals living with hemophilia.
Most of the treatment factors we administer are generously provided through the Humanitarian Aid Program of the World Federation of Hemophilia (WFH). Due to the limited supply, implementing a prophylaxis protocol remains a challenge in our HTCs. We sincerely appreciate WFH’s continued support through factor donations and the WBDR HTC Support Awards, which are invaluable to our operations.
Our dedicated HTC nursing staff regularly participates in online training programs organized by the WFH WBDR team, which has significantly enhanced the quality of care we provide.
We proudly celebrated World Hemophilia Day (WHD) 2025 through a series of impactful events. These included an awareness rally, a scientific session, and a round-table discussion involving key stakeholders such as the Rotary Club, Director General of Health Services, Ministry of Health, university authorities, social workers, and representatives from print and electronic media.
I am honored to serve as the Chief Coordinator for the development of the National Hemophilia Guideline, which has now been finalized and is awaiting official declaration.
The Government of Bangladesh has also extended support in purchasing clotting factors for selected government HTCs. However, HTC, BSMMU and HTC, Lab One Foundation (LOF) are non-governmental organizations and thus rely entirely on humanitarian aid and philanthropic contributions. HTC LOF operates 24/7 with full emergency facilities, including a blood bank, laboratory, operating theatre, and a dedicated team of doctors, nurses, and support staff.
One of our patients, Sadian, a 17 years old with Hemophilia A who has developed inhibitors, is currently receiving treatment with Emicizumab.
Given our ongoing needs and the rising number of patients, I would like to kindly request WFH to consider extending their support further through factor donations and WBDR HTC Support Awards.
We remain hopeful that World Hemophilia Day 2025 will mark a new era in ensuring access for all, especially in line with WFH’s current focus on bleeding disorders in women and girls.
Warm regards,
Prof. Dr. Md. Salahuddin Shah
Professor of Hematology
Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh